I haven't seen any direct results for inflammation with tirzepatide. The adverse events are lower than other GLP-1 agonists and very few serious adverse events. This is most likely due to tirzepatide being a duel GLP-1 and gastric inhibitory polypeptide (GIP) agonist . Activating GIP increases the level of insulin production so a lower level of GLP-1 antagonism would be needed to have the same or better effect. Lower GLP-1 activation seems to indicate lower AEs and SAEs.